Ritlecitinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), CIPM (Spain) and DMC (Denmark), among others, recommended or restricted ritlecitinib, while AOTMIT (Poland) and NYE METODER (Norway) did not recommend it.
The record spans 3.3 years, opening at AWMSG (Wales) on 9 Jan 2023 and running to 26 May 2026.
TLV (Sweden) changed its position: not recommended on 25 Mar 2025, recommended by 26 May 2026, after a resubmission.
No assessment is on file from HAS (France), PBAC (Australia), PHARMAC (New Zealand) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 12 of 12 records date from 2023 or later.
3 distinct indication wordings are recorded for ritlecitinib by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess ritlecitinib, on 9 Jan 2023; NYE METODER (Norway) did not open a file until 7 Dec 2025 — a moderate spread of 2.9 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 4 years in total.
2 of the 10 agencies here assessed ritlecitinib more than once, TLV (Sweden) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for ritlecitinib.
The full ledger for ritlecitinib reads 6 recommended, 3 not recommended, 1 restricted and 1 appraised, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 7 Dec 2025 | Behandling av alvorlig alopecia areata (flekkvist håravfall) hos pasienter fra 12 år | not introduced | source |
| DMC (Denmark) | 21 May 2025 | Svær alopecia areata hos voksne og unge på 12 år og derover | Anbefalet | source |
| TLV (Sweden) | 25 Mar 2025 | Litfulo ingår inte i läkemedelsförmånerna | rejection or exclusion | source |
| AOTMIT (Poland) | 31 Jan 2025 | Litfulo reimbursement recommendation | not recommended | source |
| ZIN (Netherlands) | 23 Oct 2024 | Advies - vergoed ritlecitinib (Litfulo®) voor de behandeling van ernstige alopecia areata | reimbursed | source |
7 further decisions for ritlecitinib, across 6 agencies, are not shown here. They include the most recent record on file, 26 May 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 12 decisions for ritlecitinib from 10 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.